UNLABELLED: A retrospective analysis was performed in order to evaluate prognostic factors and treatment-related outcome in patients with uterine papillary serous carcinoma (UPSC). PATIENTS AND METHODS: Between 1989 and 2003 forty-five patients with UPSC were treated at the McGill University Health Centre (MUHC), and therefore were included in the analysis. Age, race, history, tumor stage and grade, invasion and metastasis, treatment and outcome for each patient were evaluated. RESULTS: According to FIGO classification, Stage I, II, III, and IV tumors were identified in 36%, 9%, 44%, and 11% of the patients, respectively. At the time of analysis, 37.8% of patients (17/45) were dead due to disease, with a mean survival of 22 months (SD +/- 7.5 months). Cause-specific survival for the entire group was 69%, 66%, and 58% at 2, 3, and 5 years, respectively. With respect to disease stage, 5-year cause-specific survival for stage I, II, III, and IV was 100%, 75%, 43%, and 0%, respectively. Univariate analysis comparing cause-specific survival curves demonstrated a statistically significant difference for disease stage (p < 0.0001) and depth of myometrial invasion (p = 0.008). However, in multivariate analysis, only disease stage had a significant impact on cause-specific survival (p < 0.01). CONCLUSION: Disease stage is the only independent significant prognostic factor regarding cause-specific survival in patients with UPSC.
UNLABELLED: A retrospective analysis was performed in order to evaluate prognostic factors and treatment-related outcome in patients with uterine papillary serous carcinoma (UPSC). PATIENTS AND METHODS: Between 1989 and 2003 forty-five patients with UPSC were treated at the McGill University Health Centre (MUHC), and therefore were included in the analysis. Age, race, history, tumor stage and grade, invasion and metastasis, treatment and outcome for each patient were evaluated. RESULTS: According to FIGO classification, Stage I, II, III, and IV tumors were identified in 36%, 9%, 44%, and 11% of the patients, respectively. At the time of analysis, 37.8% of patients (17/45) were dead due to disease, with a mean survival of 22 months (SD +/- 7.5 months). Cause-specific survival for the entire group was 69%, 66%, and 58% at 2, 3, and 5 years, respectively. With respect to disease stage, 5-year cause-specific survival for stage I, II, III, and IV was 100%, 75%, 43%, and 0%, respectively. Univariate analysis comparing cause-specific survival curves demonstrated a statistically significant difference for disease stage (p < 0.0001) and depth of myometrial invasion (p = 0.008). However, in multivariate analysis, only disease stage had a significant impact on cause-specific survival (p < 0.01). CONCLUSION: Disease stage is the only independent significant prognostic factor regarding cause-specific survival in patients with UPSC.
Authors: Ashley S Felix; Joel L Weissfeld; Roslyn A Stone; Robert Bowser; Mamatha Chivukula; Robert P Edwards; Faina Linkov Journal: Cancer Causes Control Date: 2010-07-14 Impact factor: 2.506
Authors: Louise A Brinton; Ashley S Felix; D Scott McMeekin; William T Creasman; Mark E Sherman; David Mutch; David E Cohn; Joan L Walker; Richard G Moore; Levi S Downs; Robert A Soslow; Richard Zaino Journal: Gynecol Oncol Date: 2013-02-26 Impact factor: 5.482